BioSpace News Archive

Active Biotech and its partner NeoTX announce the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox, in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer who have been previously treated with chemotherapy and checkpoint inhibitors.

Rubius Therapeutics, Inc. announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 2:30 p.m. EDT.

Dyve Biosciences, Inc. announced that Chuck Harbert, Ph.D., Chief Scientific Officer of Dyve and additional members of management will be attending the Biotechnology Innovation Organization Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022.

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, announced its speaker lineup for Antibody Engineering & Therapeutics Europe, which is being held on June 7-9, 2022 in Amsterdam and online.

Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET.

TFF Pharmaceuticals, Inc. announced that President and CEO Glenn Mattes will be participating in the Jefferies Healthcare Conference being held June 8 – 10, 2022 in New York City.

aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 2022 Jefferies Healthcare Conference, which is scheduled to take place June 8 – 10, 2022, in New York, NY.

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced that serdexmethylphenidate (SDX), the novel prodrug of dexmethylphenidate (d-MPH), has significantly lower potential for abuse and fewer stimulant-like adverse events compared to d-MPH.

Microbion Corporation announced that the company will present a poster highlighting the in vitro activity of pravibismane against M. avium and M. abscessus non-tuberculous mycobacteria at the Colorado Mycobacteria Conference 2022: Focus on NTM conference taking place from May 31 to June 3, 2022, at Colorado State University.

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) for a planned Phase 1a/1b dose escalation and expansion trial to evaluate AB248.